S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
NASDAQ:FATE

Fate Therapeutics (FATE) Stock Forecast, Price & News

$23.73
+1.09 (+4.81%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$22.88
$24.05
50-Day Range
$21.45
$42.39
52-Week Range
$20.49
$97.43
Volume
1.18 million shs
Average Volume
1.40 million shs
Market Capitalization
$2.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.69
30 days | 90 days | 365 days | Advanced Chart
Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Fate Therapeutics logo

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Sales & Book Value

Annual Sales
$55.85 million
Book Value
$7.11 per share

Profitability

Net Income
$-212.15 million
Net Margins
-368.76%
Pretax Margin
-368.76%

Debt

Price-To-Earnings

Miscellaneous

Free Float
78,675,000
Market Cap
$2.29 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/18/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

587th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

97th out of 210 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics
or view top-rated stocks.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Fate Therapeutics
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.08. The biopharmaceutical company earned $18.40 million during the quarter, compared to the consensus estimate of $9.01 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 34.89% and a negative net margin of 368.76%. The firm's quarterly revenue was up 65.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.48) earnings per share.
View Fate Therapeutics' earnings history
.

What price target have analysts set for FATE?

9 equities research analysts have issued 1 year price objectives for Fate Therapeutics' shares. Their forecasts range from $60.00 to $116.00. On average, they anticipate Fate Therapeutics' share price to reach $87.22 in the next year. This suggests a possible upside of 267.6% from the stock's current price.
View analysts' price targets for Fate Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the following people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres & Director (Age 52, Pay $926.25k) (LinkedIn Profile)
  • Mr. Edward J. Dulac III, CFO & Principal Accounting Officer (Age 46, Pay $476.25k) (LinkedIn Profile)
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 49, Pay $585k) (LinkedIn Profile)
  • Dr. Bahram Valamehr Ph.D., Chief R&D Officer (Age 45, Pay $585k)
  • Dr. Mark Plavsic D.V.M., Ph.D., Chief Technical Officer
  • Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
  • Dr. Sarah Cooley, Sr. VP of Clinical Translation
  • Dr. Yu-Waye Chu M.D., Chief Medical Officer
  • Dr. Jerome Bressi Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance
What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.40%), Vanguard Group Inc. (7.96%), BlackRock Inc. (7.35%), Bellevue Group AG (3.70%), State Street Corp (3.59%) and Artal Group S.A. (2.07%). Company insiders that own Fate Therapeutics stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics
.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, SG Americas Securities LLC, Bellevue Group AG, Goldman Sachs Group Inc., Ally Bridge Group NY LLC, Citigroup Inc., JPMorgan Chase & Co., and Principal Financial Group Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, and Yu-Waye Chu.
View insider buying and selling activity for Fate Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was acquired by a variety of institutional investors in the last quarter, including Deep Track Capital LP, State Street Corp, ARK Investment Management LLC, Brown Advisory Inc., Eversept Partners LP, Artal Group S.A., Invesco Ltd., and Comerica Bank.
View insider buying and selling activity for Fate Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $23.73.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $2.29 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212.15 million in net income (profit) each year or ($2.430010) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 449 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.